The Effect of Changes in Cost Sharing on the Consumption of Prescription and Over-the-Counter Medicines in Catalonia
- PMID: 33806543
- PMCID: PMC7967646
- DOI: 10.3390/ijerph18052562
The Effect of Changes in Cost Sharing on the Consumption of Prescription and Over-the-Counter Medicines in Catalonia
Abstract
Many universal health care systems have increased the share of the price of medicines paid by the patient to reduce the cost pressure faced after the Great Recession. This paper assesses the impact of cost-sharing changes on the propensity to consume prescription and over-the-counter medicines in Catalonia, a Spanish autonomous community, affected by three new cost-sharing policies implemented in 2012. We applied a quasi-experimental difference-in-difference method using data from 2010 to 2014. These reforms were heterogeneous across different groups of individuals, so we define three intervention groups: (i) middle-income working population-co-insurance rate changed from 40% to 50%; (ii) low/middle-income pensioners-from free full coverage to 10% co-insurance rate; (iii) unemployed individuals without benefits-from 40% co-insurance rate to free full coverage. Our control group was the low-income working population whose co-insurance rate remained unchanged. We estimated the effects on the overall population as well as on the group with long-term care needs. We evaluated the effect of these changes on the propensity to consume prescription or over-the-counter medicines, and explored the heterogeneity effects across seven therapeutic groups of prescription medicines. Our findings showed that, on average, these changes did not significantly change the propensity to consume prescription or over-the-counter medicines. Nonetheless, we observed that the propensity to consume prescription medicines for mental disorders significantly increased among unemployed without benefits, while the consumption of prescribed mental disorders medicines for low/middle-income pensioners with long-term care needs decreased after becoming no longer free. We conclude that the propensity to consume medicines was not affected by the new cost-sharing policies, except for mental disorders. However, our results do not preclude potential changes in the quantity of medicines individuals consume.
Keywords: cost-sharing; healthcare financing; prescription drugs; public policy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Paying for formerly free medicines in Spain after 1 year of co-payment: changes in the number of dispensed prescriptions.Appl Health Econ Health Policy. 2014 Jun;12(3):279-87. doi: 10.1007/s40258-014-0097-6. Appl Health Econ Health Policy. 2014. PMID: 24696429
-
The effect of a change in co-payment on prescription drug demand in a National Health System: The case of 15 drug families by price elasticity of demand.PLoS One. 2019 Mar 27;14(3):e0213403. doi: 10.1371/journal.pone.0213403. eCollection 2019. PLoS One. 2019. PMID: 30917142 Free PMC article.
-
Physician and Patient Adjustment to Reference Pricing for Drugs.JAMA Netw Open. 2020 Feb 5;3(2):e1920544. doi: 10.1001/jamanetworkopen.2019.20544. JAMA Netw Open. 2020. PMID: 32022881
-
A systematic umbrella review of the association of prescription drug insurance and cost-sharing with drug use, health services use, and health.BMC Health Serv Res. 2022 Mar 3;22(1):297. doi: 10.1186/s12913-022-07554-w. BMC Health Serv Res. 2022. PMID: 35241088 Free PMC article.
-
Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies.Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):263-277. doi: 10.1080/14737167.2019.1567335. Epub 2019 Jan 24. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 30628493
References
-
- OECD/EU . Health at a Glance: Europe 2018: State of Health in the EU Cycle. OECD Publishing; Paris, France: Brussels, Belgium: 2018. - DOI
-
- Barnieh L., Clement F., Harris A., Blom M., Donaldson C., Klarenbach S., Husereau D., Lorenzetti D., Manns B. A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the Organization for Economics Co-operation and Development. PLoS ONE. 2014;9:e90434. doi: 10.1371/journal.pone.0090434. - DOI - PMC - PubMed
-
- Lopez-Valcarcel B.G., Puig-Junoy J., Feijo S.R. Fedea Policy Papers. FEDEA; Madrid, Spain: 2016. Copagos sanitarios. Revisión de experiencias internacionales y propuestas de diseño; p. 4. - DOI
-
- BOE Real Decreto-ley 16/2012, de 20 de abril, de Medidas Urgentes Para Garantizar la Sostenibilidad del Sistema Nacional de Salud y Mejorar la Calidad y Seguridad de sus Prestaciones. [Recurso Electrónico] Boletín Oficial del Estado, nu’m.98 de 24 de abril de 2012. Madrid. [(accessed on 28 July 2019)];2012 Available online: https://www.boe.es/eli/es/rdl/2012/04/20/16/con.
-
- Puig-Junoy J. The Triple Aim for the Future of Health Care. FUNCAS Social and Economic Studies; Madrid, Spain: 2015. The role of co-payments in public universal healthcare systems; pp. 101–120.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources